NCYT Novacyt S.a.

TIDMNCYT

RNS Number : 9294C

Novacyt S.A.

20 June 2019

Novacyt S.A.

("Novacyt" or the "Company")

Annual General Meeting Update

Paris, France and Camberley, UK - 20 June 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, met to hold its Annual General and Extraordinary General Shareholders' Meeting in Paris yesterday. The meeting was not deemed quorate due to the required minimum number of voting rights under French company law not being present or represented at the meeting. Therefore, a new Annual General and Extraordinary General Shareholders' Meeting will be held on 18(th) July 2019 at 2.00 p.m. (GMT) location to be confirmed.

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Matthew Johnson / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång

+44 (0)203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell

+44 (0)20 3727 1000

brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com

Mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette

+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NOACKKDQBBKDAAB

(END) Dow Jones Newswires

June 20, 2019 08:55 ET (12:55 GMT)

Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024